Our study provides new evidence that inhibition of 1B/(−)IRE DMT1 expression, per se or through RelA-Lys310 hypo-acetylation, might be a potential therapeutic approach to counteract post-ischemic neurodegeneration in stroke patients. This evidence concerns the gene SLC11A2 and Stroke.